Press "Enter" to skip to content

Salima Hacein-Bey-Abina.

Salima Hacein-Bey-Abina, Pharm .D., Ph.D., Julia Hauer, M.D., Annick Lim, M.Sci., Capucine Picard, M.D., Ph.D., Gary P. Wang, M.D., Ph.D., Charles C. Berry, Ph.D., Chantal Martinache, M.Sci.D., Sylvain Latour, Ph.D., Bernd H. Belohradsky, M.D., Lily Leiva, Ph.D., Ricardo Sorensen, M.D.D., Jean Laurent Casanova, M.D., Ph.D., Stephane Blanche, M.D., Anne Durandy, M.D., Ph.D., Frederic D. Bushman, Ph.D., Alain Fischer, M.D., Ph.D., and Marina Cavazzana-Calvo, M.D., Ph.D.1 Naturally occurring mutations in IL2RG are responsible for X-linked serious combined immunodeficiency disease.

Among the 1162 patients, all known attempted dosages had been in adherence for 79 percent, 92 percent, and 86 percent of individuals in the low-dosage, medium-dose, and high-dose organizations, respectively . Platelet doses based on at-issue platelet counts were within the patient’s assigned range for 71 percent, 80 percent, and 70 percent of transfusions in the low-dose group, medium-dosage group, and high-dosage group, respectively . This result confirms that the platelet-selection procedure usually resulted in transfusions of at-issue doses in the assigned range.